|Bid||70.05 x 800|
|Ask||70.05 x 900|
|Day's Range||69.82 - 73.85|
|52 Week Range||69.82 - 101.47|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||45.95|
|Earnings Date||Nov 03, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||102.00|
WILMINGTON, Del., September 22, 2021--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
The stock market got off to a strong start on Wednesday, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) benefited from more positive sentiment on Wall Street. As of 10 a.m. EDT, the Nasdaq was up more than half a percent, continuing to claw back some of the ground it lost in Monday's large sell-off. Both Facebook (NASDAQ: FB) and Incyte (NASDAQ: INCY) moved lower on Wednesday morning, reacting to news items that for one of the companies seemed more positive than problematic.
Shares of Incyte Corp. were down 4.0% in premarket trading on Wednesday, the day after the company announced that the Food and Drug Administration had approved Opzelura as a treatment for some patients with mild to moderate atopic dermatitis. The FDA approval for the topical drug came with a warning for serious adverse events - also referred to a black-box warning - that is consistent with oral JAK inhibitors, according to Mizuho Americas analysts. "Bigger picture, this marks yet another approva